CD1D and neoplasm: To evaluate the antitumor capacity of PBMC-iNKT cells, we used an established in vitro human melanoma A375-CD1d-FG and lung cancer H292-CD1d-FG tumor cell killing assays with or without the addition of αGC; PBMC-Tc cells were included as controls (Figure 2A).